Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cendakimab in moderate to severe atopic dermatitis
jRCT2011210011Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of cendakimab in atopic dermatitis (AD) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percent change in Eczema Area and Severity Index from baseline at Week 16. Started Aug 2021; status: completed.
02
Drugs
cendakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2011210011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210011.